Clinical trial · Observational
BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The BESPOKE CRC study will prospectively enroll patients who have undergone surgery for stage I to IV colorectal cancer (CRC) and who have residual formalin-fixed paraffin-embedded (FFPE) tissue available will provide FFPE and whole blood samples. Patients will receive SIGNATERA™ test results and may be recommended for post-operative systemic therapy or observation by their treating clinician. Patients will be followed for up to two years with periodic whole blood collection. The study also has a control arm that will consist of matched Stage I to IV CRC cases that have a minimum of least 2 years clinical follow-up data.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Cancer | Malignant Colon Neoplasm | CURATED_EXACT | 0.92 |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Prospective arm
- description
- Patients who have undergone surgery for stage I to IV colorectal cancer (CRC) and who have residual formalin-fixed paraffin-embedded (FFPE) tissue available will provide FFPE and whole blood samples. Patients will receive SIGNATERA™ test results and may be recommended for adjuvant chemotherapy or observation by their treating clinician. Patients will be followed for up to two years with periodic whole blood collection. Treatment administered, disease-free survival, overall survival, time to recurrence, physician questionnaires and patient-reported outcomes will be recorded.
- label
- Control Arm
- description
- The control arm will consist of matched Stage I to Stage IV CRC cases using the following criteria: sex, age of diagnosis and ECOG performance prior to ACT, and a minimum of 3 evaluations per year. The patient cases would have a minimum of 2 years follow-up data and received treatment no more than 3 years prior to study start date.
Primary outcomes (2)
- measure
- Examine the impact of SIGNATERA™ on adjuvant treatment decisions
- timeFrame
- 1 years
- description
- The study will examine the percent of patients who have their adjuvant treatment regimen increased or decreased after the treating physician evaluates the results from the post-surgical SIGNATERA™ ctDNA test for patients with Stage II and Stage III CRC.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion criteria: 1. 18 years of age or older. 2. Planning or undergone surgical resection of adenocarcinoma of the colon or rectum. 3. Diagnosis of Colorectal cancer that falls into one of the below categories: 1. Stage I to IV disease. 2. Stage IV with oligometastatic disease eligible for post-operative systemic therapy. 4. Selected by their healthcare provider to receive the SIGNATERA™ test according to the current evidence-informed schedule as part of their routine practice. 5. ECOG performance status ≤ 2 6. Clinically eligible for post-operative systemic therapy. 7. Able to tolerate venipuncture for research blood draw(s). 8. Able to read, understand and provide written informed consent . 9. Willing and able to comply with the study requirements. Exclusion Criteria: 1. Pregnant or breastfeeding. 2. Prior history and treatment for any cancer within the past year or has another active cancer, with the exception of non-melanoma skin cancer 3. Has a known rare inherited genetic condition, with the exception of lynch syndrome 4. Has initiated post-operative systemic therapy. 5. Neuropathy \> grade 2. 6. History of bone marrow or organ transplant. 7. Medical condition that would place the patient at risk as a result of blood donation, such as bleeding disorder . 8. Serious medical condition that may adversely affect ability to participate in the study. Control Arm Inclusion criteria: 1. 18 years of age or older at time of diagnosis. 2. Diagnosis of Colorectal cancer that falls into one of the below categories: 1. Stage I to IV disease. 2. Stage IV with oligometastatic disease eligible for post-operative systemic therapy. 3. Were clinically eligible for chemotherapy at full recommended doses per Health Care Provider. 4. Received treatment no more than 3 years prior to study start date. 5. Have a minimum of least 2 years clinical follow-up data or reached a progression event. Control Arm Exclusion criteria: 1. Female patients that were pregnant or breastfeeding during historical control collection period. 2. Per investigator, was not clinically eligible for post-operative systemic therapy. 3. Had an ECOG performance status ≤ 2 at time of diagnosis.
References
Publications (1)
- DERIVEDKasi PM, Sawyer S, Guilford J, Munro M, Ellers S, Wulff J, Hook N, Krinshpun S, Koyen Malashevich A, Malhotra M, Rodriguez A, Moshkevich S, Grothey A, Kopetz S, Billings P, Aleshin A. BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer. BMJ Open. 2021 Sep 24;11(9):e047831. doi: 10.1136/bmjopen-2020-047831. PMID 34561256